Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The Trump administration has proposed cutting a $56 million grant that teaches first responders how to use the lifesaving overdose reversal drug naloxone, which experts say could reverse progress the ...

Courtesy Lowenthal For decades, people suffering life-threatening allergic reactions had to quickly and correctly give ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

A new nasal spray that uses a form of ketamine to treat stubborn depression will be added to the PBS, making treatment ...

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...